Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce the availability of its new CRYOcheck Chromogenic Factor VIII assay in Canada, the European Union, Australia, and New Zealand following market authorization by Health Canada and respective in-country regulatory authorities.
CRYOcheck Chromogenic Factor VIII is intended for use by clinical labs for the determination of FVIII activity in human plasma and as an aid in the management of hemophilia A. Studies1 have shown the chromogenic method to be less prone to interference from lipids or traces of heparin than clot-based FVIII activity tests, offering unsurpassed assurance in results, especially in cases of severe hemophilia A.